SBWire

Global Markets Direct's, 'Lymphangioleiomyomatosis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lymphangioleiomyomatosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphangioleiomyomatosis. Lymphangioleiomyomatosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

"PharmaSphere: Healthcare Information Technology Software and Services Report - Vertical Market Analysis of Leading IT Business Process Outsourcing and Electronic Medical Record Vendors" report discusses the various platforms, service models, and go-to-market strategies of the major players in the IT BPO, and EMR markets. The research provides an assessment of vendor strategies, outsourcing agreements, significant deals and corporate developments, and contract vehicles signed by these BPO and EMR firms over the past three years.

Global Market Direct's pharmaceuticals report, "Isarna Therapeutics GmbH - Product Pipeline Review - 2014" provides data on the Isarna Therapeutics GmbH's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

BioGanix recently released their new weight loss product, Yacon Root Extract Premium 1000, and consumers need to take note. One common concern with supplements is the question of natural and organic or synthetic. This latest product represents an improvement over Yacon Syrup extract products, as Bioganix is one of the first companies to release an organic and 100% pure version of Yacon Syrup Extract.

GlobalData's clinical trial report, "Leg Ulcers Global Clinical Trials Review, H1, 2014" provides data on the Leg Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Leg Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Leg Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Cutaneous Mastocytosis Global Clinical Trials Review, H1, 2014" provides data on the Cutaneous Mastocytosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cutaneous Mastocytosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cutaneous Mastocytosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Market Direct's pharmaceuticals report, "Trophos SA - Product Pipeline Review - 2014" provides data on the Trophos SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Genzyme Corporation - Product Pipeline Review - 2014" provides data on the Genzyme Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Motif BioSciences, Inc. - Product Pipeline Review - 2014" provides data on the Motif BioSciences, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

GlobalData's clinical trial report, "Bruise Global Clinical Trials Review, H1, 2014" provides data on the Bruise clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bruise. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bruise. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Market Direct's pharmaceuticals report, "Bioniche Life Sciences, Inc. - Product Pipeline Review - 2014" provides data on the Bioniche Life Sciences, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Sareum Holdings plc - Product Pipeline Review - 2014" provides data on the Sareum Holdings plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Epistem Holdings Plc - Product Pipeline Review - 2014" provides data on the Epistem Holdings Plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Bone Marrow Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Simcere Pharmaceutical Group - Product Pipeline Review - 2014" provides data on the Simcere Pharmaceutical Group's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "MabVax Therapeutics, Inc. - Product Pipeline Review - 2014" provides data on the MabVax Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

MedVax Technologies, Inc. , a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference on Wednesday, January 15, 2014 at 1:45 p.m. Pacific (10:45 a.m. Eastern) at the Parc 55 Wyndham - Union Square, San Francisco, CA.

GlobalData's clinical trial report, "Xerosis (Dry Skin) Global Clinical Trials Review, H1, 2014" provides data on the Xerosis (Dry Skin) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Xerosis (Dry Skin). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Xerosis (Dry Skin). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

After being recommended by weight loss experts, and having been found to be effective at promoting weight loss in clinical studies, garcinia cambogia has quickly become very popular with dieters.

OTC Medications in Indonesia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2013. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Indonesia is given in IDR with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Indonesia. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Global Markets Direct's, 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

GlobalData's clinical trial report, "Strabismus Global Clinical Trials Review, H1, 2014" provides data on the Strabismus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Strabismus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Strabismus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players